PMID- 23480493
OWN - NLM
STAT- MEDLINE
DCOM- 20140508
LR  - 20190116
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 54
IP  - 11
DP  - 2013 Nov
TI  - Prognostic markers and their clinical applicability in chronic lymphocytic 
      leukemia: where do we stand?
PG  - 2351-64
LID - 10.3109/10428194.2013.783913 [doi]
AB  - Chronic lymphocytic leukemia (CLL) is a clinically and biologically heterogeneous 
      disease where the majority of patients have an indolent disease course, while 
      others may experience a far more aggressive disease, treatment failure and poor 
      overall survival. During the last two decades, there has been an intense search 
      to find novel biomarkers that can predict prognosis as well as guide treatment 
      decisions. Two of the most reliable molecular prognostic markers, both of which 
      are offered in routine diagnostics, are the immunoglobulin heavy chain variable 
      (IGHV) gene mutational status and fluorescence in situ hybridization (FISH) 
      detection of prognostically relevant genomic aberrations (e.g. 11q-, 13q-, +12 
      and 17p-). In addition to these markers, a myriad of additional biomarkers have 
      been postulated as potential prognosticators in CLL, on the protein (e.g. CD38, 
      ZAP70, TCL1), the RNA (e.g. LPL, CLLU1, micro-RNAs) and the genomic (e.g. TP53, 
      NOTCH1, SF3B1 and BIRC3 mutations) level. Efforts are now being made to test 
      these novel markers in larger patient cohorts as well as in prospective trials, 
      with the ultimate goal to combine the "best" markers in a "CLL prognostic index" 
      applicable for the individual patient. Although it is clear that these studies 
      have significantly improved our knowledge regarding both prognostication and the 
      biology of the disease, there is still an immediate need for recognizing 
      biomarkers that can predict therapy response, and efforts should now focus on 
      addressing this pertinent issue. In the present article, we review the extensive 
      literature in the field of prognostic markers in CLL, focus on the most 
      clinically relevant markers and discuss future directions regarding biomarkers in 
      CLL.
FAU - Rosenquist, Richard
AU  - Rosenquist R
AD  - Department of Immunology, Genetics and Pathology, Uppsala University , Uppsala , 
      Sweden.
FAU - Cortese, Diego
AU  - Cortese D
FAU - Bhoi, Sujata
AU  - Bhoi S
FAU - Mansouri, Larry
AU  - Mansouri L
FAU - Gunnarsson, Rebeqa
AU  - Gunnarsson R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130430
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Biomarkers, Tumor)
SB  - IM
CIN - Leuk Lymphoma. 2014 Apr;55(4):964-5. PMID: 23865830
MH  - *Biomarkers, Tumor/genetics/metabolism
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*diagnosis/genetics/metabolism
MH  - Neoplasm Staging
MH  - Prognosis
EDAT- 2013/03/14 06:00
MHDA- 2014/05/09 06:00
CRDT- 2013/03/14 06:00
PHST- 2013/03/14 06:00 [entrez]
PHST- 2013/03/14 06:00 [pubmed]
PHST- 2014/05/09 06:00 [medline]
AID - 10.3109/10428194.2013.783913 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2013 Nov;54(11):2351-64. doi: 10.3109/10428194.2013.783913. Epub 
      2013 Apr 30.